777 related articles for article (PubMed ID: 33514385)
1. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
2. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
4. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
[TBL] [Abstract][Full Text] [Related]
6. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
[TBL] [Abstract][Full Text] [Related]
7. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
8. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
[TBL] [Abstract][Full Text] [Related]
9. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
[TBL] [Abstract][Full Text] [Related]
10. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
[TBL] [Abstract][Full Text] [Related]
11. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
[TBL] [Abstract][Full Text] [Related]
12. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
[TBL] [Abstract][Full Text] [Related]
14. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
15. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2.
Tang Q; Owens RJ; Naismith JH
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835020
[TBL] [Abstract][Full Text] [Related]
16. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization.
Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X
J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467
[TBL] [Abstract][Full Text] [Related]
17. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
Mast FD; Fridy PC; Ketaren NE; Wang J; Jacobs EY; Olivier JP; Sanyal T; Molloy KR; Schmidt F; Rutkowska M; Weisblum Y; Rich LM; Vanderwall ER; Dambrauskas N; Vigdorovich V; Keegan S; Jiler JB; Stein ME; Olinares PDB; Herlands L; Hatziioannou T; Sather DN; Debley JS; Fenyö D; Sali A; Bieniasz PD; Aitchison JD; Chait BT; Rout MP
Elife; 2021 Dec; 10():. PubMed ID: 34874007
[TBL] [Abstract][Full Text] [Related]
18. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
Custódio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Hällberg BM; Löw C
Nat Commun; 2020 Nov; 11(1):5588. PubMed ID: 33149112
[TBL] [Abstract][Full Text] [Related]
19. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
20. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
